Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States

Luciano J. Costa, Ilene K. Brill, James Omel, Kelly Godby, Shaji K. Kumar, Elizabeth E. Brown

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Prior improvements in multiple myeloma (MM) survival were not fully observed in racial and ethnic minorities and older individuals. We hypothesized that improvements in MM management in recent years have reduced these disparities. We used the Surveillance, Epidemiology, and End Results registries to calculate the incidence and relative survival rates (RSRs) of MM in the United States for patients diagnosed from 1993 to 1997 (prethalidomide), 1998 to 2002 (introduction of thalidomide), 2003 to 2007 (bortezomib and lenalidomide), and 2008 to 2012 (upfront bortezomib and lenalidomide, early availability of carfilzomib and pomalidomide). MM incidence increased significantly among non-Hispanic whites (NHWs) and non-Hispanic black (NHB) men, but not among NHB women and Hispanics. Improvement in 5-year RSRs (1993-1997 vs 2008-2012) was seen among patients of all age and race/ethnicity groups. Ten-year RSRs (1993-1997 vs 2003-2007) improved for patients,65 years of age (19.6%-35%; P, .001), but not for patients $75 years of age (7.8%-9.3%; P 5 .3). Among patients 65 to 74 years of age, 10-year RSRs improved for NHWs (11.3% vs 20.5%; P, .001) and Hispanics (10.6% vs 20.2%; P 5 .02), but not for NHBs (12.6% vs 19.5%; P 5 .06.). These findings confirm consistent improvement in survival for MM patients and point to the challenge of further extending these improvements to older and minority patients.

Original languageEnglish (US)
Pages (from-to)282-287
Number of pages6
JournalBlood Advances
Volume1
Issue number4
DOIs
StatePublished - Jan 1 2017

Fingerprint

Multiple Myeloma
Survival
Incidence
Survival Rate
Hispanic Americans
Thalidomide
Registries
Epidemiology

ASJC Scopus subject areas

  • Hematology

Cite this

Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. / Costa, Luciano J.; Brill, Ilene K.; Omel, James; Godby, Kelly; Kumar, Shaji K.; Brown, Elizabeth E.

In: Blood Advances, Vol. 1, No. 4, 01.01.2017, p. 282-287.

Research output: Contribution to journalArticle

Costa, Luciano J. ; Brill, Ilene K. ; Omel, James ; Godby, Kelly ; Kumar, Shaji K. ; Brown, Elizabeth E. / Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. In: Blood Advances. 2017 ; Vol. 1, No. 4. pp. 282-287.
@article{82c6111d3b124d6a9a64c95821d6e6c7,
title = "Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States",
abstract = "Prior improvements in multiple myeloma (MM) survival were not fully observed in racial and ethnic minorities and older individuals. We hypothesized that improvements in MM management in recent years have reduced these disparities. We used the Surveillance, Epidemiology, and End Results registries to calculate the incidence and relative survival rates (RSRs) of MM in the United States for patients diagnosed from 1993 to 1997 (prethalidomide), 1998 to 2002 (introduction of thalidomide), 2003 to 2007 (bortezomib and lenalidomide), and 2008 to 2012 (upfront bortezomib and lenalidomide, early availability of carfilzomib and pomalidomide). MM incidence increased significantly among non-Hispanic whites (NHWs) and non-Hispanic black (NHB) men, but not among NHB women and Hispanics. Improvement in 5-year RSRs (1993-1997 vs 2008-2012) was seen among patients of all age and race/ethnicity groups. Ten-year RSRs (1993-1997 vs 2003-2007) improved for patients,65 years of age (19.6{\%}-35{\%}; P, .001), but not for patients $75 years of age (7.8{\%}-9.3{\%}; P 5 .3). Among patients 65 to 74 years of age, 10-year RSRs improved for NHWs (11.3{\%} vs 20.5{\%}; P, .001) and Hispanics (10.6{\%} vs 20.2{\%}; P 5 .02), but not for NHBs (12.6{\%} vs 19.5{\%}; P 5 .06.). These findings confirm consistent improvement in survival for MM patients and point to the challenge of further extending these improvements to older and minority patients.",
author = "Costa, {Luciano J.} and Brill, {Ilene K.} and James Omel and Kelly Godby and Kumar, {Shaji K.} and Brown, {Elizabeth E.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1182/bloodadvances.2016002493",
language = "English (US)",
volume = "1",
pages = "282--287",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States

AU - Costa, Luciano J.

AU - Brill, Ilene K.

AU - Omel, James

AU - Godby, Kelly

AU - Kumar, Shaji K.

AU - Brown, Elizabeth E.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Prior improvements in multiple myeloma (MM) survival were not fully observed in racial and ethnic minorities and older individuals. We hypothesized that improvements in MM management in recent years have reduced these disparities. We used the Surveillance, Epidemiology, and End Results registries to calculate the incidence and relative survival rates (RSRs) of MM in the United States for patients diagnosed from 1993 to 1997 (prethalidomide), 1998 to 2002 (introduction of thalidomide), 2003 to 2007 (bortezomib and lenalidomide), and 2008 to 2012 (upfront bortezomib and lenalidomide, early availability of carfilzomib and pomalidomide). MM incidence increased significantly among non-Hispanic whites (NHWs) and non-Hispanic black (NHB) men, but not among NHB women and Hispanics. Improvement in 5-year RSRs (1993-1997 vs 2008-2012) was seen among patients of all age and race/ethnicity groups. Ten-year RSRs (1993-1997 vs 2003-2007) improved for patients,65 years of age (19.6%-35%; P, .001), but not for patients $75 years of age (7.8%-9.3%; P 5 .3). Among patients 65 to 74 years of age, 10-year RSRs improved for NHWs (11.3% vs 20.5%; P, .001) and Hispanics (10.6% vs 20.2%; P 5 .02), but not for NHBs (12.6% vs 19.5%; P 5 .06.). These findings confirm consistent improvement in survival for MM patients and point to the challenge of further extending these improvements to older and minority patients.

AB - Prior improvements in multiple myeloma (MM) survival were not fully observed in racial and ethnic minorities and older individuals. We hypothesized that improvements in MM management in recent years have reduced these disparities. We used the Surveillance, Epidemiology, and End Results registries to calculate the incidence and relative survival rates (RSRs) of MM in the United States for patients diagnosed from 1993 to 1997 (prethalidomide), 1998 to 2002 (introduction of thalidomide), 2003 to 2007 (bortezomib and lenalidomide), and 2008 to 2012 (upfront bortezomib and lenalidomide, early availability of carfilzomib and pomalidomide). MM incidence increased significantly among non-Hispanic whites (NHWs) and non-Hispanic black (NHB) men, but not among NHB women and Hispanics. Improvement in 5-year RSRs (1993-1997 vs 2008-2012) was seen among patients of all age and race/ethnicity groups. Ten-year RSRs (1993-1997 vs 2003-2007) improved for patients,65 years of age (19.6%-35%; P, .001), but not for patients $75 years of age (7.8%-9.3%; P 5 .3). Among patients 65 to 74 years of age, 10-year RSRs improved for NHWs (11.3% vs 20.5%; P, .001) and Hispanics (10.6% vs 20.2%; P 5 .02), but not for NHBs (12.6% vs 19.5%; P 5 .06.). These findings confirm consistent improvement in survival for MM patients and point to the challenge of further extending these improvements to older and minority patients.

UR - http://www.scopus.com/inward/record.url?scp=85028708659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028708659&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2016002493

DO - 10.1182/bloodadvances.2016002493

M3 - Article

C2 - 29296944

AN - SCOPUS:85028708659

VL - 1

SP - 282

EP - 287

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 4

ER -